Sign In
Buy ALZN
$1.22
+0 (+0%)
At Close: Jun 22, 2026
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonate Superior Brain Penetration: AL001 showed numerically higher
Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patients Topline data expected in third
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?
01:38am, Tuesday, 13'th Jan 2026
Shares of Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) dropped 2.5% on Monday. The stock traded as low as $2.20 and last traded at $2.33. Approximately 43,364 shares were traded during mid-da
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why
02:14am, Saturday, 22'nd Nov 2025
Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) shares were down 0.5% on Friday. The company traded as low as $1.95 and last traded at $1.96. Approximately 72,560 shares changed hands during mid
Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharm
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
08:00am, Monday, 28'th Jul 2025
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
08:00am, Wednesday, 23'rd Jul 2025
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alza
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
08:00am, Monday, 16'th Jun 2025
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Al
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetic
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetic
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetic
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:55am, Tuesday, 08'th Apr 2025
After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of A
